Vericiguat for Heart Failure with Reduced Ejection Fraction

Area of Science:

• Cardiovascular medicine
• Pharmacology

Background:

• The nitric oxide (NO)-soluble guanylate cyclase (sGC)-cyclic guanosine monophosphate (cGMP) pathway is crucial for cardiovascular regulation but is impaired in heart failure (HF).
• In HF, reduced NO bioavailability and altered sGC redox state diminish NO responsiveness, compromising cardioprotection.

Purpose of the Study:

• To review the role of the NO-sGC-cGMP pathway in heart failure.
• To evaluate the therapeutic potential of sGC modulators, including activators and stimulators, in managing HF.

Main Methods:

• Review of clinical trials and pharmacological mechanisms of sGC activators and stimulators.
• Analysis of data on vericiguat's efficacy in high-risk heart failure patients.

Main Results:

• sGC activators (e.g., cinaciguat) increase cGMP independently of NO but carry a risk of hypotension.
• sGC stimulators (e.g., vericiguat, riociguat) enhance sensitivity to endogenous NO, offering a more physiological approach.
• Vericiguat demonstrated a reduced incidence of cardiovascular death or HF hospitalization in high-risk patients with HF and reduced ejection fraction (HFrEF).

Conclusions:

• Vericiguat may be a valuable addition for select high-risk HFrEF patients, particularly those prone to HF hospitalization.
• Targeting the NO-sGC-cGMP pathway with stimulators like vericiguat represents a promising therapeutic strategy in heart failure management.